- Drugmaker’s stock has fallen about 14% to start the year
- Yearly sales outlook for Covid pill, shot missed estimates
Shares of Pfizer Inc. suffered their biggest monthly decline since June 2020 as investors anticipated a troubled path ahead for the drugmaker’s Covid products.
The stock slumped 14% this month, erasing US$40 billion in market value. In its earnings report on Tuesday, Pfizer presented a weaker-than-estimated sales outlook for its Covid vaccine and pill. Shares fluctuated between gains and losses before ending the day higher by 1.4% amid a broader market rally.
“PFE was already widely expected to guide below consensus – and the ’23 guide delivered on that,” Barclays analyst Carter Gould, who has a hold-equivalent rating on the stock, wrote in a note. Given the stock’s decline so far this month, “there had been hope for a bounce once the print was out of the way, however, we’re skeptical that will materialize in the near-term.”
Pfizer’s shares got a boost throughout the pandemic as its Covid-19 vaccine and pill brought in billions of dollars in sales.
The 2023 guidance miss was “widely anticipated” and was the reason shares had been weak heading into the report, Cantor Fitzgerald analyst Louise Chen, who holds a buy-equivalent rating on the stock, wrote in a note.
by Breanna Bradham
Join: 👉 https://t.me/acnewspatriots
The opinions expressed by contributors and/or content partners are their own and do not necessarily reflect the views of AC.NEWS
Disclaimer: This article may contain statements that reflect the opinion of the author. The contents of this article are of sole responsibility of the author(s). AC.News will not be responsible for any inaccurate or incorrect statement in this article www.ac.news websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner. Reprinting this article: Non-commercial use OK. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.
Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.